Month: October 2024

Siemens Healthineers has recently received premarket approval from the FDA for the 3D imaging component of its newly redesigned mammography system, the Mammomat B.brilliant. This marks the company’s first major overhaul of its mammography platform in more than a decade. The approval highlights a significant advancement in the use of 3D imaging technology to enhance […]

Continue Reading

Philips recently initiated a recall for several models of its Trilogy ventilators due to a range of issues that potentially endanger patients by not providing sufficient ventilation or oxygen. The affected models include the Trilogy Evo, Trilogy EV300, Trilogy Evo O2, and Trilogy Evo Universal. This recall, affecting approximately 90,000 units globally—with about 67,000 located […]

Continue Reading

Eli Lilly has introduced a promising obesity treatment drug targeting two metabolic pathways, shedding significant weight and showing potential for substantial revenue generation. This innovative approach has spurred other pharmaceutical companies to enhance and replicate Lilly’s strategy. Among these companies, Kailera Therapeutics emerges as a significant player, entering the scene with robust funding support of […]

Continue Reading

GE Healthcare has achieved a significant milestone by securing approval from the Food and Drug Administration (FDA) for Flyrcado (flurpiridaz F 18), a new imaging agent designed for positron emission tomography (PET) scans, which are utilized in the detection of coronary artery disease. This cutting-edge agent boasts a notably longer half-life compared to existing tracers […]

Continue Reading

The Food and Drug Administration (FDA) has yet to issue new guidelines aimed at correcting racial disparities in the accuracy of pulse oximeters, despite initial announcements that new rules would be released by September 30. This delay follows revelations nearly four years ago that these devices, which measure blood oxygen levels, frequently fail to detect […]

Continue Reading